ArticleTherapeutic advances in medical oncology2022

Corrigendum to "GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)".

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.